Loading...
Genomic and epigenomic analyses in recent years have shed light on the marked molecular heterogeneity that underpins clinical presentation and treatment response in patients with acute myeloid leukemia (AML). Investigators have now performed a multicenter analysis of AML patients enrolled in three prospective clinical trials of intensive induction therapy.
Cytogenetic analysis and sequencing of 111 genes relevant to AML were characterized as to the types and frequency of mutations and the interactions among the identified molecular abnormalities. A Bayesian statistical model was used to segregate AML into subgoups based on comutations and correlate them with overall survival (OS).
In the 1540 patients analyzed, a remarkable 5240 driver mutati…